Treatment with clot-busting drug yields better results after stroke than supportive therapy alone

Public release date: 7-Feb-2013 [ | E-mail | Share ]

Contact: Stephanie Desmon sdesmon@jhmi.edu 410-955-8665 Johns Hopkins Medicine

In an update to previous research, Johns Hopkins neurologists say minimally invasive delivery of the drug tPA directly into potentially lethal blood clots in the brain helped more patients function independently a year after suffering an intracerebral hemorrhage (ICH), a deadly and debilitating form of stroke. Rates of functional recovery with the active tPA treatment far surpassed those achieved with standard "supportive" therapy that essentially gives clots a chance to shrink on their own.

In the current Johns Hopkins-led study, ICH patients who randomly received the minimally invasive surgery to deliver a drug designed to dissolve their golf ball-sized clots went home from the hospital an average of 38 days sooner than those receiving supportive therapy. In addition to the health benefits, the tPA therapy, and resulting shortened hospital stay, led to a savings of an estimated $44,000 per patient, the researchers say. ICH has long been considered surgically untreatable under most circumstances; roughly 50 percent of people who have such a stroke die from it.

"This is the most promising treatment that has come along in the last 30 or 40 years for people who have suffered hemorrhagic stroke," says study leader Daniel F. Hanley, M.D., a professor of neurology at the Johns Hopkins University School of Medicine. Hanley is scheduled to present the study's findings at the International Stroke Conference in Honolulu, Hawaii, Feb. 6 through Feb. 8.

Evidence for the value of active use of the clot-busting drug emerged from follow-up visits of 96 patients from 25 medical centers, all between the ages 18 to 80. Hanley says he hopes this will lead to a larger study of 500 patients. Hanley says the larger-scale study should provide enough information to determine definitively whether the intervention can transform the practice of caring for brain hemorrhage. The drug tPA (tissue plasminogen activator) has long been used to dissolve clots in the lung and those formed by heart attacks involving major blood vessels. Historically, tPA has not been considered appropriate for hemorrhagic stroke patients.

Participants in the Minimally Invasive Surgery plus tPA for Intracerebral Hemorrhage Evacuation (MISTIE) trial were treated at the 25 sites in the United States, Canada and Europe. Surgeons at each site performed the procedure by drilling a dime-sized hole in each patient's skull close to the clot location. Using a CT scan that Hanley likens to "GPS for the brain," they guided the catheter through the hole and directly into the clot. The catheter was then used to drip small doses of tPA into the clot for several days, shrinking the clots roughly 20 percent per day. Those patients who underwent supportive therapy saw their clots shrink by about 5 percent per day.

Hanley says the treatment got rid of much of the clot safely, without cutting through easily damaged brain tissue or removing large pieces of the skull.

"This procedure is technically simple, the equipment and the type of trained physicians needed are available across the country, and if our findings hold up in the larger study we hope to perform, then this therapy could be widely adopted," Hanley says. "It could not only bring benefit to patients but also save money."

ICH is marked by bleeding from a blood vessel in the brain that causes a clot to form and is often caused by uncontrolled blood pressure. The clot builds up pressure in the brain and leaches inflammatory chemicals that can cause irreversible brain damage, often leading to death or extreme disability. The standard of care for ICH patients is general supportive care, usually in an ICU, that includes intense blood pressure control, artificial ventilation, drugs to control swelling and watchful waiting for the clot to dissipate on its own. Invasive surgery is reserved for patients who deteriorate. Currently, only 10 percent of patients undergo the risky and more invasive craniotomy surgery, which involves removing a portion of the skull and making incisions through healthy brain tissue to reach and remove the clot.

More:
Treatment with clot-busting drug yields better results after stroke than supportive therapy alone